Microbes have long been the focus of researchers in medicine, and there are now hundreds of them.
The new microbicide, a type of bacterial peptide, is one of the first to be approved by the US Food and Drug Administration (FDA) and may be able to be used to treat infections of some types of bacterial skin cancer, according to the journal Nature Communications.
The study, conducted by researchers from the University of North Carolina, has been published in the journal Molecular Therapy.
The peptide was found to have a high affinity for the receptors on the surface of certain bacteria.
Researchers say that this could be a boon for the treatment of cancer.
The peptides work on a single enzyme, which then uses its ability to bind with other enzymes to turn a compound into a living bacterium.
The new peptides target a different type of bacteria, and have been found to be more effective against many different types of bacteria.
This means that they could be used in other forms of drug therapy, as well.
This could be useful in the future, as the ability to use them to treat other infections could be critical.
Researchers have already discovered the ability of bacteria to use chemical reactions to make antibiotics.
The next step is to test the peptides on mice, so that they can be used for other kinds of bacterial infections as well, such as those caused by Pseudomonas and other types of viral infections.
“We’re excited about the potential of this new class of peptides to help treat a wide range of bacterial diseases,” said lead researcher and first author Dr Michael J. Meeks, a professor of biological sciences at the University at Albany.
“Our work demonstrates the promise of this class of antibiotics to be able, in future, to be effective against infections of the skin and in many other different types, such in chronic infections such as skin cancer.”
The research was funded by the National Institutes of Health, the National Science Foundation, and the Department of Defense.